Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Vipoma 1Somatostatinoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1

Interventions

telotristat ethyl 4lutetium Lu 177 dotatate 43-Iodobenzylguanidine 3vandetanib 2pasireotide 2gallium Ga 68 dotatate 2Temozolomide 2Octreotide 2Biological Therapy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1trametinib 1pembrolizumab 1lanreotide 1fosbretabulin 1farletuzumab 1dabrafenib 1combretastatin 1ceritinib 1antineoplaston AS 2-1 1antineoplaston A10 1Tretinoin 1Tranexamic Acid 1Solutions 1Saline Solution 1Panitumumab 1Paclitaxel 1Microarray Analysis 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × vatalanib × Endocrine × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡